EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TPMT and NUDT15 Pharmacogenomic Profiles in Peruvian Patients With Pediatric Hematologic Malignancies

Julio A Poterico, Francisco Sánchez-Pinto, Gerardo Noriega-Manrique, Kelly Franco-Bustamante, Gioconda Manassero-Morales, Julissa Fuentes-Vera, Luis Jaramillo-Valverde, Alicia Mafaldo-Rengifo, Jorge Contreras-Saavedra

Frontiers in Bioscience-Scholar · 2026

DOI: 10.31083/fbs50635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Scholar, 2026. Verfasst von Julio A Poterico und 8 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Genética, Instituto Nacional de Salud del Niño-San Borja, 15037 Lima, Peru. Hauptthemen laut MEDLINE: Pyrophosphatases, Methyltransferases, Hematologic Neoplasms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Nacional de Salud del Niño San Borja (INSN-SB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thiopurines remain a cornerstone of treatment for pediatric acute lymphoblastic leukemia (ALL); however, interindividual variability in drug metabolism, largely driven by polymorphisms in the thiopurine S-methyltransferase (TPMT) and nucleoside diphosphate–linked moiety X–type motif 15 (NUDT15) genes, can predispose patients to severe, dose-dependent toxicities. Latin American populations have been underrepresented in several global pharmacogenomic (PGx) datasets, limiting the applicability of current dosing recommendations.

Methods

Thus, this study aimed to analyze TPMT and NUDT15 variants in 302 pediatric patients diagnosed with hematological malignancies at the Instituto Nacional de Salud del Niño-San Borja (INSN-SB). Targeted sequencing of the coding regions was performed using custom AmpliSeq™ panels and Illumina platforms, followed by variant annotation and star allele classification based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB guidelines.

Results

Among the TPMT alleles, *3A (8.97%) was the most prevalent actionable variant, followed by *2 (0.32%) and *3C (0.32%). For NUDT15, the most frequent reduced-function allele was *2 (9.29%), with additional findings of *4 (0.64%), *6 (0.32%), *3 (0.16%), and *15 (0.16%). A substantial proportion of the cohort was classified as intermediate or poor metabolizer categories, indicating an increased risk of thiopurine-related toxicity. The observed allele distribution suggests potential geographic variation, although these patterns should be interpreted as exploratory given the limited regional sample size.

Conclusions

This study provides one of the first comprehensive characterizations of clinically relevant TPMT and NUDT15 variants in a Peruvian pediatric population. The findings highlight a substantial burden of actionable pharmacogenetic variants and support the implementation of preemptive genotyping to guide thiopurine dosing. These results help addressing the underrepresentation of Latin American populations in PGx research and provide a foundation for advancing precision medicine in the region.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrophosphatasesMethyltransferasesHematologic NeoplasmsHumansChildNudix HydrolasesFemaleChild, PreschoolPeruMaleAdolescentInfantPharmacogeneticsPrecursor Cell Lymphoblastic Leukemia-LymphomaMercaptopurineAlleles

Stichwörter der Autor:innen

NUDT15geneticindigenous peoplespharmacogeneticspolymorphismprecursor cell lymphoblastic leukemia-lymphomathiopurine S-methyltransferase

Substanzen

NUDT15 protein, humanPyrophosphatasesNudix HydrolasesTPMT protein, humanMethyltransferasesMercaptopurine

Autor:innen und Institutionen

  • Servicio de Genética, Instituto Nacional de Salud del Niño-San Borja, 15037 Lima, Peru.
  • Faculty of Health Sciences, Universidad de Huánuco, 10001 Huánuco, Peru.
  • Facultad de Ciencias Biológicas, Universidad Nacional Mayor de San Marcos, 15081 Lima, Peru.
  • School of Medicine, Universidad Continental, 12000 Huancayo, Peru.
  • Servicio de Hematología Clínica, Instituto Nacional de Salud del Niño-San Borja, 15037 Lima, Peru.
  • Servicio de Transplante de Progenitores Hematopoyéticos, Instituto Nacional de Salud del Niño-San Borja, 15037 Lima, Peru.

Förderung

  • Instituto Nacional de Salud del Niño San Borja (INSN-SB)

Zitieren

APA

Poterico, J. A., Sánchez-Pinto, F., Noriega-Manrique, G., Franco-Bustamante, K., Manassero-Morales, G., Fuentes-Vera, J., Jaramillo-Valverde, L., Mafaldo-Rengifo, A., & Contreras-Saavedra, J. (2026). TPMT and NUDT15 Pharmacogenomic Profiles in Peruvian Patients With Pediatric Hematologic Malignancies. Frontiers in Bioscience-Scholar. https://doi.org/10.31083/fbs50635

Vancouver

Poterico JA, Sánchez-Pinto F, Noriega-Manrique G, Franco-Bustamante K, Manassero-Morales G, Fuentes-Vera J, et al. TPMT and NUDT15 Pharmacogenomic Profiles in Peruvian Patients With Pediatric Hematologic Malignancies. Frontiers in Bioscience-Scholar. 2026. doi:10.31083/fbs50635

BibTeX
@article{Poterico2026,
  author = {Poterico, Julio A and Sánchez-Pinto, Francisco and Noriega-Manrique, Gerardo and Franco-Bustamante, Kelly and Manassero-Morales, Gioconda and Fuentes-Vera, Julissa and Jaramillo-Valverde, Luis and Mafaldo-Rengifo, Alicia and Contreras-Saavedra, Jorge},
  title = {TPMT and NUDT15 Pharmacogenomic Profiles in Peruvian Patients With Pediatric Hematologic Malignancies},
  journal = {Frontiers in Bioscience-Scholar},
  year = {2026},
  doi = {10.31083/fbs50635}
}
Kostenlos starten →